Market Summary
USD59.08+0.30
Market Closed0.51%
BMY Stock Price
BMY RSI Chart
BMY Valuation
BMY Price/Sales (Trailing)
BMY Profitability
BMY Fundamentals
BMY Revenue
BMY Earnings
Price Action
52 Week Range
58.3381.44
(Low)(High)
Last 7 days
-0.7%
Last 30 days
-4.5%
Last 90 days
-9.2%
Trailing 12 Months
-14.3%
BMY Financial Health
BMY Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for BMY
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-24 | Powell Ann | sold | -1,101,640 | 61.25 | -17,986 | evp, chief human resources |
2023-08-03 | Plenge Robert M | sold | -44,754 | 61.14 | -732 | evp, chief research officer |
2023-07-01 | Weese Michelle | acquired | - | - | 1,885 | evp, corporate affairs |
2023-07-01 | Hirawat Samit | sold (taxes) | -306,129 | 63.95 | -4,787 | evp,chief med.offr.,drug dev. |
2023-07-01 | Hirawat Samit | acquired | - | - | 9,357 | evp,chief med.offr.,drug dev. |
2023-07-01 | Weese Michelle | sold (taxes) | -43,613 | 63.95 | -682 | evp, corporate affairs |
2023-06-03 | Lenkowsky Adam | sold (taxes) | -36,178 | 65.66 | -551 | evp, chief commercial officer |
2023-06-03 | Lenkowsky Adam | acquired | - | - | 1,077 | evp, chief commercial officer |
2023-05-03 | VESSEY RUPERT | sold | -3,378,820 | 67.06 | -50,385 | evp & president, research |
2023-05-02 | Greenlees Sharon | acquired | - | - | 1,017 | svp & controller |
Which funds bought or sold BMY recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-19 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | added | 0.35 | -228,812 | 2,858,120 | 1.20% |
2023-09-18 | WASHINGTON CAPITAL MANAGEMENT, INC | unchanged | - | -27,872 | 332,540 | 0.28% |
2023-09-14 | IMS Capital Management | added | 0.25 | -31,184 | 384,929 | 0.21% |
2023-09-14 | Proquility Private Wealth Partners, LLC | added | 0.16 | -97,698 | 1,190,360 | 0.47% |
2023-09-12 | DCM Advisors, LLC | sold off | -100 | -213,891 | - | -% |
2023-09-12 | Farther Finance Advisors, LLC | added | 325 | 936,805 | 1,256,810 | 0.28% |
2023-09-11 | Dechtman Wealth Management, LLC | new | - | 640,987 | 640,987 | 0.19% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | reduced | -6.8 | -1,000 | 6,139 | -% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 1,456,140 | 1,456,140 | 0.08% |
2023-09-07 | JAG CAPITAL MANAGEMENT, LLC | reduced | -16.66 | -74,653 | 248,580 | 0.03% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Bristol-Myers Squibb
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 9.54% | 202,927,620 | SC 13G/A | |
| Feb 07, 2023 | blackrock inc. | 8.1% | 172,720,377 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 9.00% | 199,834,483 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 7.6% | 169,226,706 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 8.82% | 199,340,458 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 7.6% | 172,464,804 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 8.32% | 194,860,154 | SC 13G/A | |
| Feb 05, 2020 | blackrock inc. | 7.3% | 171,343,446 | SC 13G/A | |
| Jan 28, 2020 | wellington management group llp | 3.57% | 83,470,877 | SC 13G/A |
Recent SEC filings of Bristol-Myers Squibb
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 28, 2023 | 4 | Insider Trading | |
| Aug 24, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 10, 2023 | 8-K | Current Report | |
| Aug 07, 2023 | 4 | Insider Trading | |
| Aug 03, 2023 | 144 | Notice of Insider Sale Intent | |
| Jul 27, 2023 | 10-Q | Quarterly Report | |
| Jul 27, 2023 | 8-K | Current Report | |
| Jul 05, 2023 | 4 | Insider Trading | |
| Jul 05, 2023 | 3 | Insider Trading | |
| Jul 05, 2023 | 4 | Insider Trading |
Peers (Alternatives to Bristol-Myers Squibb)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 495.0B | 29.5B | -0.64% | 86.07% | 76.18 | 16.77 | 1.53% | 14.16% |
JNJ | 420.1B | 97.8B | -2.63% | 0.36% | 32.18 | 4.3 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -0.47% | 27.98% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 185.5B | 77.9B | -10.83% | -24.56% | 8.64 | 2.38 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -4.49% | -14.30% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.73% | 596.48% | -74.02 | 4.1K | -86.94% | 71.24% |
PRGO | 4.4B | 4.6B | -13.48% | -15.45% | -65.31 | 0.95 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
TLRY | 1.6B | 627.1M | -7.75% | -19.97% | -1.08 | 2.5 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -13.44% | -19.42% | 34.58 | 2.36 | 0.62% | -24.59% |
INVA | 843.4M | 244.3M | -2.42% | 7.48% | 4.28 | 3.45 | -39.50% | -4.99% |
CRON | 807.9M | 109.5M | 20.45% | -29.10% | -5.63 | 7.38 | -2.66% | -32.13% |
ACRS | 482.6M | 31.2M | -9.55% | -49.48% | -4.58 | 15.49 | 407.54% | -26.47% |
CGC | 422.3M | 453.3M | 90.89% | -73.90% | -0.34 | 0.93 | -16.04% | 55.90% |
OCUL | 258.3M | 54.6M | -16.41% | -43.89% | -2.85 | 4.73 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
Bristol-Myers Squibb News
Returns for BMY
Cumulative Returns on BMY
5.1%
10-Year Cumulative Returns
3.4%
7-Year Cumulative Returns
1.6%
5-Year Cumulative Returns
3.1%
3-Year Cumulative Returns
Risks for BMY
What is the probability of a big loss on BMY?
45%
Probability that Bristol-Myers Squibb stock will be more than 20% underwater in next one year
1.9%
Probability that Bristol-Myers Squibb stock will be more than 30% underwater in next one year.
0%
Probability that Bristol-Myers Squibb stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BMY drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Bristol-Myers Squibb was unfortunately bought at previous high price.
Drawdowns
Financials for Bristol-Myers Squibb
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -1.4% | 45,187 | 45,848 | 46,159 | 46,738 | 47,144 | 46,960 | 46,385 | 45,468 | 44,384 | 42,810 | 42,518 | 39,395 | 34,862 | 31,006 | 26,145 | 24,173 | 23,857 | 23,288 | 22,561 | 22,037 | 21,600 |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 30,745 | 28,040 | 24,219 | 21,090 | 18,067 | 16,819 | 16,794 | 16,384 | - | - | - |
| Costs and Expenses | -1.5% | 36,490 | 37,052 | 38,446 | 39,026 | 39,484 | 39,705 | 38,287 | 49,679 | 48,495 | 46,847 | 49,389 | 35,944 | 32,319 | 28,314 | 21,170 | 17,564 | 16,430 | 17,120 | 16,593 | 16,876 | 17,423 |
| S&GA Expenses | 1.9% | 7,892 | 7,745 | 7,814 | 7,902 | 7,760 | 7,855 | 7,690 | 8,057 | 7,975 | 7,721 | 7,661 | 6,674 | 6,023 | 5,471 | 4,871 | 4,473 | 4,522 | 4,577 | 4,551 | 4,531 | 4,590 |
| R&D Expenses | -0.7% | 9,507 | 9,570 | 9,509 | 9,517 | 10,079 | 10,236 | 10,195 | 10,332 | 9,851 | 9,895 | 10,048 | 9,490 | 8,369 | 7,172 | 6,148 | 5,418 | 5,320 | 6,430 | 6,332 | 6,890 | 7,171 |
| EBITDA | -100.0% | - | 18,917 | 17,989 | 19,446 | 19,546 | 19,355 | 20,284 | 8,200 | 8,228 | 8,134 | 5,109 | 12,791 | 9,399 | 7,159 | 7,135 | 7,491 | 8,303 | 7,032 | 6,805 | 6,023 | 5,062 |
| EBITDA Margin | -100.0% | - | 0.41* | 0.39* | 0.42* | 0.42* | 0.41* | 0.44* | 0.18* | 0.19* | 0.19* | 0.12* | 0.32* | 0.27* | 0.23* | 0.27* | 0.31* | 0.35* | 0.30* | 0.30* | 0.27* | 0.23* |
| Earnings Before Taxes | -1.1% | 8,697 | 8,796 | 7,713 | 7,712 | 7,660 | 7,255 | 8,098 | -4,211 | -4,111 | -4,037 | -6,871 | 3,451 | 2,543 | 2,692 | 4,975 | 6,609 | 7,427 | 6,168 | 5,968 | 5,161 | 4,177 |
| EBT Margin | -100.0% | - | 0.19* | 0.17* | 0.17* | 0.16* | 0.15* | 0.17* | -0.09* | -0.09* | -0.09* | -0.16* | 0.09* | 0.07* | 0.09* | 0.19* | 0.27* | 0.31* | 0.26* | 0.26* | 0.23* | 0.19* |
| Net Income | 8.9% | 7,963 | 7,311 | 6,327 | 6,677 | 6,617 | 6,251 | 6,994 | -5,405 | -5,079 | -6,219 | -9,015 | -44.00 | -563 | 954 | 3,439 | 5,655 | 6,203 | 5,144 | 4,920 | 1,432 | 376 |
| Net Income Margin | -100.0% | - | 0.16* | 0.14* | 0.14* | 0.14* | 0.13* | 0.15* | -0.12* | -0.11* | -0.15* | -0.21* | 0.00* | -0.02* | 0.03* | 0.13* | 0.23* | 0.26* | 0.22* | 0.22* | 0.06* | 0.02* |
| Free Cashflow | -100.0% | - | 11,081 | 11,948 | 12,725 | 14,281 | 15,142 | 15,234 | 14,884 | 11,687 | 13,242 | 13,299 | 11,842 | 12,409 | 9,896 | 7,374 | 7,583 | 6,272 | 5,239 | 4,989 | 3,713 | 4,109 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -0.8% | 93,489 | 94,281 | 96,820 | 98,196 | 100,357 | 103,034 | 109,314 | 110,893 | 110,797 | 112,435 | 118,481 | 125,536 | 128,076 | 129,285 | 129,944 | 57,433 | 55,163 | 34,834 | 34,986 | 33,734 | 32,641 |
| Current Assets | 3.6% | 28,074 | 27,086 | 27,273 | 26,796 | 30,186 | 30,121 | 33,262 | 31,443 | 29,161 | 27,111 | 30,192 | 34,277 | 34,343 | 31,853 | 29,354 | 40,191 | 37,716 | 17,093 | 17,716 | 14,869 | 13,874 |
| Cash Equivalents | -6.9% | 8,372 | 8,995 | 9,123 | 7,734 | 10,960 | 12,579 | 14,316 | 13,879 | 11,397 | 11,321 | 14,973 | 19,860 | 20,362 | 16,246 | 12,820 | 30,489 | 28,404 | 7,335 | 6,911 | 5,408 | 4,999 |
| Inventory | -9.3% | 2,364 | 2,605 | 2,339 | 2,074 | 2,142 | 2,104 | 2,095 | 2,163 | 2,137 | 1,953 | 2,074 | 1,949 | 2,384 | 2,836 | 4,293 | 1,192 | 1,308 | 1,283 | 1,195 | 1,282 | 1,242 |
| Net PPE | 1.2% | 6,355 | 6,279 | 6,255 | 6,035 | 5,970 | 6,047 | 6,049 | 5,868 | 5,795 | 5,763 | 5,886 | 5,740 | 5,777 | 6,112 | 6,252 | 4,830 | 4,849 | 4,985 | 5,027 | 5,092 | 5,080 |
| Goodwill | 0.0% | 21,163 | 21,162 | 21,149 | 21,112 | 20,446 | 20,500 | 20,502 | 20,519 | 20,529 | 20,524 | 20,547 | 20,517 | 20,578 | 22,452 | 22,488 | 6,513 | 6,533 | 6,536 | 6,538 | 6,686 | 6,683 |
| Liabilities | -1.5% | 61,459 | 62,395 | 65,702 | 65,462 | 67,696 | 71,389 | 73,308 | 73,609 | 73,923 | 74,762 | 80,599 | 75,306 | 78,916 | 79,308 | 78,246 | 39,679 | 39,012 | 19,517 | 20,859 | 19,984 | 20,223 |
| Current Liabilities | 5.6% | 20,150 | 19,085 | 21,890 | 18,930 | 20,915 | 22,821 | 21,868 | 21,460 | 18,991 | 17,330 | 19,080 | 20,464 | 23,421 | 19,232 | 18,304 | 10,489 | 9,711 | 8,841 | 10,654 | 9,694 | 9,878 |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 50,336 | 44,614 | 46,106 | 46,105 | 46,150 | 24,390 | 24,433 | 5,635 | - | - | - |
| LT Debt, Non Current | -1.2% | 34,656 | 35,078 | 35,056 | 36,966 | 37,107 | 37,450 | 39,605 | 39,677 | 42,503 | 44,505 | 48,336 | 41,364 | 41,853 | 42,844 | 43,387 | 24,390 | 24,433 | 5,635 | 5,646 | 5,687 | 5,671 |
| Shareholder's Equity | 0.5% | 31,973 | 31,824 | 31,061 | 32,671 | 32,600 | 31,580 | 35,946 | 37,213 | 36,808 | 37,605 | 37,822 | 50,230 | 49,160 | 49,977 | 51,598 | 17,754 | 16,151 | 15,317 | 14,031 | 13,750 | 12,418 |
| Retained Earnings | 3.3% | 27,449 | 26,568 | 25,503 | 24,675 | 24,217 | 23,948 | 23,820 | 22,625 | 22,168 | 22,204 | 21,281 | 32,414 | 31,565 | 32,671 | 34,474 | 36,555 | 35,870 | 35,109 | 34,065 | 33,292 | 32,044 |
| Additional Paid-In Capital | 0.4% | 45,299 | 45,140 | 45,165 | 44,956 | 44,375 | 43,756 | 44,361 | 44,292 | 44,064 | 43,852 | 44,325 | 44,435 | 44,444 | 43,254 | 43,709 | 2,206 | 2,150 | 2,103 | 2,081 | 2,029 | 1,966 |
| Minority Interest | -8.1% | 57.00 | 62.00 | 57.00 | 63.00 | 61.00 | 65.00 | 60.00 | 71.00 | 66.00 | 68.00 | 60.00 | 72.00 | 66.00 | 66.00 | 100 | 106 | 102 | 99.00 | 96.00 | 110 | 101 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -3.1% | 11,850 | 12,224 | 13,066 | 13,817 | 15,396 | 16,195 | 16,207 | 15,505 | 12,506 | 13,939 | 14,052 | 12,878 | 13,167 | 10,757 | 8,210 | 9,584 | 8,307 | 7,281 | 7,066 | 4,628 | 5,062 |
| Share Based Compensation | 4.4% | 493 | 472 | 457 | 471 | 498 | 539 | 583 | 621 | 664 | 720 | 779 | 892 | 763 | 598 | 441 | 210 | 216 | 219 | 221 | 218 | 206 |
| Cashflow From Investing | -2.9% | -1,407 | -1,367 | -1,062 | -1,874 | -769 | -300 | -538 | -12,751 | -11,988 | -11,612 | -10,859 | -11,226 | -10,522 | -10,363 | -9,913 | 804 | 166 | -897 | -2,000 | 481 | 770 |
| Cashflow From Financing | 9.4% | -13,012 | -14,359 | -16,962 | -17,683 | -14,920 | -14,582 | -16,224 | -8,774 | -9,581 | -7,392 | -1,151 | -12,311 | -10,665 | 8,596 | 7,621 | 14,720 | 14,941 | -4,342 | -3,535 | -4,309 | -4,295 |
| Dividend Payments | 1.0% | 4,692 | 4,645 | 4,634 | 4,588 | 4,524 | 4,473 | 4,396 | 4,318 | 4,244 | 4,166 | 4,075 | 3,722 | 3,377 | 3,027 | 2,679 | 2,664 | 2,646 | 2,629 | 2,613 | 2,599 | 2,586 |
| Buy Backs | 26.9% | 4,272 | 3,367 | 8,001 | 8,452 | 8,276 | 9,512 | 6,287 | 5,001 | 4,476 | 3,240 | 1,546 | 7,081 | 7,381 | 7,381 | 7,300 | 300 | - | 153 | 320 | 569 | 789 |
BMY Income Statement
2023-06-30CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |||
| Total revenues | $ 11,226 | $ 11,887 | $ 22,563 | $ 23,535 | ||
| Cost of products sold | [1] | 2,876 | 2,720 | 5,442 | 5,191 | |
| Marketing, selling and administrative | 1,934 | 1,787 | 3,696 | 3,618 | ||
| Research and development | 2,258 | 2,321 | 4,579 | 4,581 | ||
| Acquired IPRD | 158 | 400 | 233 | 733 | ||
| Amortization of acquired intangible assets | 2,257 | 2,417 | 4,513 | 4,834 | ||
| Other (income)/expense, net | (116) | 284 | (529) | 933 | ||
| Total Expenses | 9,367 | 9,929 | 17,934 | 19,890 | ||
| Earnings before income taxes | 1,859 | 1,958 | 4,629 | 3,645 | ||
| Income tax (benefit)/provision | (218) | 529 | 285 | 933 | ||
| Net earnings | 2,077 | 1,429 | 4,344 | 2,712 | ||
| Noncontrolling interest | 4 | 8 | 9 | 13 | ||
| Net earnings attributable to BMS | $ 2,073 | $ 1,421 | $ 4,335 | $ 2,699 | ||
| Earnings per common share: | ||||||
| Basic (usd per share) | $ 0.99 | $ 0.67 | $ 2.07 | $ 1.26 | ||
| Diluted (usd per share) | $ 0.99 | $ 0.66 | $ 2.06 | $ 1.25 | ||
| Net product sales | ||||||
| Total revenues | $ 10,917 | $ 11,485 | $ 21,965 | $ 22,793 | ||
| Alliance and other revenues | ||||||
| Total revenues | $ 309 | $ 402 | $ 598 | $ 742 | ||
| ||||||
BMY Balance Sheet
2023-06-30CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 8,372 | $ 9,123 |
| Marketable debt securities | 358 | 130 |
| Receivables | 10,112 | 9,886 |
| Inventories | 2,364 | 2,339 |
| Other current assets | 6,868 | 5,795 |
| Total Current assets | 28,074 | 27,273 |
| Property, plant and equipment | 6,355 | 6,255 |
| Goodwill | 21,163 | 21,149 |
| Other intangible assets | 31,303 | 35,859 |
| Deferred income taxes | 1,572 | 1,344 |
| Other non-current assets | 5,022 | 4,940 |
| Total Assets | 93,489 | 96,820 |
| Current liabilities: | ||
| Short-term debt obligations | 3,020 | 4,264 |
| Accounts payable | 3,069 | 3,040 |
| Other current liabilities | 14,061 | 14,586 |
| Total Current liabilities | 20,150 | 21,890 |
| Deferred income taxes | 751 | 2,166 |
| Long-term debt | 34,656 | 35,056 |
| Other non-current liabilities | 5,902 | 6,590 |
| Total Liabilities | 61,459 | 65,702 |
| Commitments and Contingencies | ||
| BMS Shareholders’ equity: | ||
| Preferred stock | 0 | 0 |
| Common stock | 292 | 292 |
| Capital in excess of par value of stock | 45,299 | 45,165 |
| Accumulated other comprehensive loss | (1,387) | (1,281) |
| Retained earnings | 27,449 | 25,503 |
| Less cost of treasury stock | (39,680) | (38,618) |
| Total BMS Shareholders’ equity | 31,973 | 31,061 |
| Noncontrolling interest | 57 | 57 |
| Total Equity | 32,030 | 31,118 |
| Total Liabilities and Equity | $ 93,489 | $ 96,820 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.